Policy & Regulation
European Commission expands Crysvita approval to infants with XLH
21 July 2026 - Kyowa Kirin EMEA, a subsidiary of Japanese pharmaceutical company Kyowa Kirin Co Ltd (TSE:4151), said on Tuesday that the European Commission has approved an expanded indication for Cry...
Akagera Medicines reports positive first-in-human data for AKG-100
21 July 2026 - Clinical-stage biopharmaceutical company Akagera Medicines Inc, together with the TASK Clinical Research Center in South Africa, on Monday announced positive results from the single-asc...
Argo Biopharma doses first participant in Phase I trial of factor XI targeting siRNA therapy
21 July 2026 - Argo Biopharmaceutical Co Ltd, a clinical-stage small interfering RNA (siRNA) therapeutics company, announced on Monday that the first participant has been dosed in its Phase I study of...
Acadia Pharmaceuticals announces receipt of FDA Fast Track designation for remlifanserin to treat Alzheimer's disease psychosis
20 July 2026 - Acadia Pharmaceuticals (Nasdaq: ACAD), a developer of treatments for neurological and rare diseases, revealed on Monday that it has received U.S. Food and Drug Administration Fast Track...
Almirall advances Ebglyss paediatric regulatory filing in Europe
20 July 2026 - Spanish pharmaceutical company Almirall S.A. (BME:ALM) said on Monday that the European Medicines Agency has accepted its submission to extend the Marketing Authorisation Application fo...
Sareum completes dosing in Phase 2-enabling toxicology programme for SDC-1801
20 July 2026 - Biotechnology company Sareum Holdings plc (AIM: SAR) announced on Monday that it has completed dosing in the Phase 2-enabling toxicology programme for SDC-1801, its selective oral TYK2/...